AbstractBackgroundThe relationship between biochemical aspirin resistance (AR) and functional outcome of acute ischemic stroke is uncertain.MethodsProspectively, 269 patients with acute ischemic stroke were recruited. Their responsiveness to aspirin was evaluated by platelet function analyzer (PFA-100). All patients received blood tests for fibrinogen, high-sensitivity C-reactive protein (hs-CRP), CD40-ligand, P-selectin, intercellular adhesion molecule -1, von Willebrand factor (vWF), and D–dimer. The patients' National Institutes of Health Stroke Scale and modified Rankin Scale scores were recorded on admission, at 30 days, and at 90 days after stroke.ResultsClosure-time measured by PFA-100 equipped with epinephrine/collagen cartridge (Ep...
PurposeStroke is a serious complication after acute myocardial infarction (AMI) and is associated wi...
AbstractObjectivesThis study was designed to determine if aspirin resistance is associated with clin...
Background: There is a link between high on-treatment platelet reactivity (HPR) and adverse vascular...
AbstractBackgroundThe relationship between biochemical aspirin resistance (AR) and functional outcom...
We sought to investigate the clinical implications of platelet reactivity to aspirin and the variabi...
The aim of this study was to investigate the relationship between aspirin resistance, ischaemic stro...
<div><p>Background</p><p>Aspirin is a primary antiplatelet agent for the secondary prevention of isc...
Background: Aspirin use is known to reduce the recurrence of stroke. However, the clinical response ...
Background Aspirin is a primary antiplatelet agent for the secondary prevention of ischemic stroke. ...
“Aspirin resistance” (AR) is associated with increased risk of vascular events. We aimed to compare ...
Introduction: The issue of resistance to antiplatelet therapy has raised many questions in the area ...
Background: It has been reported that aspirin resistance was correlated with severity and mortality...
Background and Purpose—Recent studies suggest that patients who do not respond to aspirin (ASA) ther...
Aspirin is the most commonly used antiplatelet drug in the secondary prevention of cardiovascular ev...
BACKGROUND AND PURPOSE: Recent studies suggest that patients who do not respond to aspirin (ASA) the...
PurposeStroke is a serious complication after acute myocardial infarction (AMI) and is associated wi...
AbstractObjectivesThis study was designed to determine if aspirin resistance is associated with clin...
Background: There is a link between high on-treatment platelet reactivity (HPR) and adverse vascular...
AbstractBackgroundThe relationship between biochemical aspirin resistance (AR) and functional outcom...
We sought to investigate the clinical implications of platelet reactivity to aspirin and the variabi...
The aim of this study was to investigate the relationship between aspirin resistance, ischaemic stro...
<div><p>Background</p><p>Aspirin is a primary antiplatelet agent for the secondary prevention of isc...
Background: Aspirin use is known to reduce the recurrence of stroke. However, the clinical response ...
Background Aspirin is a primary antiplatelet agent for the secondary prevention of ischemic stroke. ...
“Aspirin resistance” (AR) is associated with increased risk of vascular events. We aimed to compare ...
Introduction: The issue of resistance to antiplatelet therapy has raised many questions in the area ...
Background: It has been reported that aspirin resistance was correlated with severity and mortality...
Background and Purpose—Recent studies suggest that patients who do not respond to aspirin (ASA) ther...
Aspirin is the most commonly used antiplatelet drug in the secondary prevention of cardiovascular ev...
BACKGROUND AND PURPOSE: Recent studies suggest that patients who do not respond to aspirin (ASA) the...
PurposeStroke is a serious complication after acute myocardial infarction (AMI) and is associated wi...
AbstractObjectivesThis study was designed to determine if aspirin resistance is associated with clin...
Background: There is a link between high on-treatment platelet reactivity (HPR) and adverse vascular...